Hi! 👋 We have a new venture. Please check out Satire Labs, our Medium post, and consider buying our first NFT, "Dumb" SolPunks 😉.
The funniest way to turn your $100 to $1 million. ⛴️ 🚢.
Note: This is a joke. Kinda. We really do think you'll make money 😎🙂

What is ALXN's Selling, General, and Administrative (SG&A)?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Selling, General, and Administrative (SG&A) is 
$1.5B (1Y +15.5% )

ALXN Stock Price & Selling, General, and Administrative (SG&A)

Selling, General, and Administrative (SG&A) for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Selling, General, and Administrative (SG&A)

chevron_right 2021 $444.4M +1110x
( +29.7% / year avg)
chevron_left 1995 $400.0K
vertical_align_top Peak $1.3B +3340x
vertical_align_bottom Bottom $400.0K
arrow_drop_up # Up Years 24 24 of 27
years up.
arrow_drop_down # Down Years 2
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.04x the rate relative to it's selling, general, and administrative (sg&a) over the same period.
  • If ALXN grows it's stock at the same rate as it's selling, general, and administrative (sg&a) (+29.7%/year) , it's stock price will grow +1,347% and hit $1464.57 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 24 years (0%) it's selling, general, and administrative (sg&a) were also up.
  • ALXN Historical Selling, General, and Administrative (SG&A) Table
    in $ million
    Year Selling, General, and Administrative (SG&A) YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $444 -66.7% - -
    4/1/2020 $1,336 11.5% - -
    4/1/2019 $1,198 10.0% - -
    4/1/2018 $1,089 3.0% - -
    4/1/2017 $1,057 49.8% - -
    4/1/2016 $705 -12.3% - -
    4/1/2015 $804 38.5% - -
    4/1/2014 $581 24.3% - -
    4/1/2013 $467 30.4% - -
    4/1/2012 $358 25.8% - -
    4/1/2011 $285 32.1% - -
    4/1/2010 $215 35.2% - -
    4/1/2009 $159 29.5% - -
    4/1/2008 $123 35.9% - -
    4/1/2007 $90 139.1% - -
    4/1/2006 $37 74.5% - -
    4/1/2005 $21 42.0% - -
    4/1/2004 $15 36.3% - -
    4/1/2003 $11 30.9% - -
    4/1/2002 $8 16.7% - -
    4/1/2001 $7 47.5% - -
    4/1/2000 $4 66.3% - -
    4/1/1999 $3 7.1% - -
    4/1/1998 $2 0.0% - -
    4/1/1997 $2 40.0% - -
    4/1/1996 $2 400.0% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company.

    For more detailed definitions, please see Investopedia.